



Al-controlled DNA switches

Precise, safe, and adaptive solutions for oncotherapy

Challenges

- High costs and long development cycles
- Side effects due to inaccurate gene activation

Solutions

- Al + MPRA create regulators active only in tumours
- Reducing the cost, timelines, and toxicity of gene therapy

Technology

Closed loop Al ← Lab



Al designs, Lab tests, Model learns

Roadmap

Platform setup

Model training

MVP and pilots

Licensing

Advantages

- ✓ AI + Lab integration
- Proprietary datasets
- ✓ Scalability

Revenue model

 Pilots
 \$200-250K

 SaaS
 \$50K/year

 Licences
 \$0.5-1M

Attracting \$1.1M

10 R&D cycles 2-3 patents and pilot launches We are creating not just a drug — we are building the infrastructure for the therapy of the future